Nanocarrier Delivery Systems for Overcoming Epilepsy Treatment Barriers

This narrative review compiles preclinical evidence on nanocarrier drug delivery platforms designed to improve brain targeting and blood-brain barrier penetration of antiepileptic agents, relevant to neuropharmacists tracking early-stage formulation science.

📅 Journal publication: Jul 3, 2026 · Last updated: Jul 30, 2026

nanocarriersnanoparticlesliposomessolid lipid nanoparticlesnanostructured lipid carriersblood-brain barrierepilepsydrug-resistant epilepsyantiseizure medicationscarbamazepinelamotriginedrug deliverynarrative reviewneuropharmacology Neurology / Neuropharmacology

Background Information

Nanocarriers show potential for improving epilepsy drug delivery.

Epilepsy treatments face challenges like poor blood-brain barrier (BBB) penetration and drug resistance, limiting their effectiveness. Nanocarriers improve the brain targeting and effectiveness of antiepileptic drugs by enhancing BBB penetration and drug stability in preclinical studies. While nanocarriers offer promising improvements in epilepsy treatment, issues such as large-scale manufacturing and regulatory approval need resolution before clinical application. Nanocarrier technology shows promise for enhancing antiepileptic drug delivery.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.

Subscribe for $8/month → Read this one free →

Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Chauhan A, Kumar A, Awasthi A, Bhatia R

Citation: Chauhan A, Kumar A, Awasthi A, et al. Nanocarrier-based targeting strategies in epilepsy: addressing pathophysiological barriers. The Journal of pharmacy and pharmacology. 2026;78(7). doi:10.1093/jpp/rgag077

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Founding member rate

$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →

Free account, no credit card. Includes 1 full deep analysis every month.

Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.